scholarly journals Splenic and portal vein thrombosis following laparoscopic splenectomy in a pediatric patient with chronic myeloid leukemia

2006 ◽  
Vol 124 (5) ◽  
pp. 275-277 ◽  
Author(s):  
Henrique Manoel Lederman ◽  
Evan Fieldston
Keyword(s):  
Magnetic Resonance ◽  
Chronic Myeloid Leukemia ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Laparoscopic Splenectomy ◽  
Myeloid Leukemia ◽  
Rare Complication ◽  
Marrow Transplant ◽  
Vein Thrombosis ◽  
Increased Risk

CONTEXT: Splenic or portal vein thrombosis is a rare complication following splenectomy. CASE REPORT: We report a case of splenic and portal venous thrombosis in a 10-year-old girl with chronic myeloid leukemia who underwent laparoscopic splenectomy prior to bone marrow transplant. Clinical suspicion of such thrombosis should be high for patients who have had splenectomy. The diagnosis is confirmed by Doppler ultrasound or contrast-enhanced computed tomography; magnetic resonance imaging magnetic resonance angiography or arteriography can also be used. Proposals for postoperative screening protocols are discussed. Patients with primary myeloproliferative disorders are at increased risk of portal vein thrombosis, independent of surgical intervention, perhaps due to platelet dysfunction resulting from abnormalities of pluripotent stem cells. Marked splenomegaly (with larger draining veins) is thought to increase the risk of thrombosis.

Massive Splenic Infarction and Portal Vein Thrombosis in Children With Chronic Myeloid Leukemia

2014 ◽  
Vol 36 (7) ◽  
pp. e471-e472 ◽  
Author(s):  
Tekin Aksu ◽  
Arzu Y. Erdem ◽  
Ali Fettah ◽  
Dilek Kaçar ◽  
Zekai Avci ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Myeloid Leukemia ◽  
Splenic Infarction ◽  
Vein Thrombosis

scholarly journals The Role of Portal Vein Thrombosis in the Clinical Course of Inflammatory Bowel Diseases: Report on Three Cases and Review of the Literature

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Emanuele Sinagra ◽  
Emma Aragona ◽  
Claudia Romano ◽  
Simonetta Maisano ◽  
Ambrogio Orlando ◽  
...  
Keyword(s):  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Inflammatory Bowel Diseases ◽  
Vascular Complications ◽  
Hepatic Abscess ◽  
Vein Thrombosis ◽  
Increased Risk ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Thromboembolism Events

Inflammatory bowel diseases are associated with an increased risk of vascular complications. The most important are arterial and venous thromboembolisms, which are considered as specific extraintestinal manifestations of inflammatory bowel diseases. Among venous thromboembolism events, portal vein thrombosis has been described in inflammatory bowel diseases. We report three cases of portal vein thrombosis occurring in patients with active inflammatory bowel disease. In two of them, hepatic abscess was present. Furthermore, we performed a systematic review based on the clinical literature published on this topic.

Transhepatic Thrombolysis in Acute Portal Vein Thrombosis After Laparoscopic Splenectomy

2002 ◽  
Vol 12 (2) ◽  
pp. 131-136 ◽  
Author(s):  
Kent W. Kercher ◽  
Ronald F. Sing ◽  
Kevin W. Watson ◽  
Brent D. Matthews ◽  
Mark H. LeQuire ◽  
...  
Keyword(s):  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Laparoscopic Splenectomy ◽  
Vein Thrombosis

scholarly journals Magnetic Resonance Thrombus Imaging to Differentiate Acute from Chronic Portal Vein Thrombosis

TH Open ◽  
2020 ◽  
Vol 04 (03) ◽  
pp. e224-e230
Author(s):  
Lisette F. van Dam ◽  
Frederikus A. Klok ◽  
Maarten E. Tushuizen ◽  
Walter Ageno ◽  
Sarwa Darwish Murad ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Test Performance ◽  
Expert Panel ◽  
Three Dimensional ◽  
Acute Thrombosis ◽  
Vein Thrombosis ◽  
Thrombus Imaging ◽  
Enhanced Computed Tomography

Abstract Introduction Timely diagnosis and treatment of portal vein thrombosis (PVT) is crucial to prevent morbidity and mortality. However, current imaging tests cannot always accurately differentiate acute from chronic (nonocclusive) PVT. Magnetic resonance noncontrast thrombus imaging (MR-NCTI) has been shown to accurately differentiate acute from chronic venous thrombosis at other locations and may also be of value in the diagnostic management of PVT. This study describes the first phase of the Rhea study (NTR 7061). Our aim was to select and optimize MR-NCTI sequences that would be accurate for differentiation of acute from chronic PVT. Study Design The literature was searched for different MRI sequences for portal vein and acute thrombosis imaging. The most promising sequences were tested in a healthy volunteer followed by one patient with acute PVT and two patients with chronic PVT, all diagnosed on (repetitive) contrast-enhanced computed tomography (CT) venography to optimize the MR-NCTI sequences. All images were evaluated by an expert panel. Results Several MR-NCTI sequences were identified and tested. Differentiation of acute from chronic PVT was achieved with 3D T1 TFE (three-dimensional T1 turbo field echo) and 3D T1 Dixon FFE (three-dimensional T1 fast field echo) sequences with best image quality. The expert panel was able to confirm the diagnosis of acute PVT on the combined two MR-NCTI sequences and to exclude acute PVT in the two patients with chronic PVT. Conclusion Using 3D T1 TFE and 3D T1 Dixon FFE sequences, we were able to distinguish acute from chronic PVT. This clinical relevant finding will be elucidated in clinical studies to establish their test performance.

scholarly journals Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis

2019 ◽  
Vol 39 (02) ◽  
pp. 195-208 ◽  
Author(s):  
Ethan Weinberg ◽  
Julia Palecki ◽  
K. Reddy
Keyword(s):  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Treatment Guidelines ◽  
Oral Anticoagulants ◽  
Primary Prophylaxis ◽  
Current Treatment ◽  
Vein Thrombosis ◽  
Increased Risk ◽  
Direct Acting ◽  
Direct Acting Oral Anticoagulants

AbstractDirect-acting oral anticoagulants (DOACs) have provided benefit in patients requiring anticoagulation for certain diseases by decreasing the burden of subcutaneous injections and the requirement for frequent monitoring through regular blood tests, to ensure adequacy of the therapeutic doses. Studies have demonstrated DOACs to be as safe, and in some instance safer, compared with traditional anticoagulants in the general population. However, the studies evaluating DOACs excluded patients with cirrhosis, a condition associated with an increased risk of developing portal vein thrombosis (PVT). Warfarin or low-molecular weight heparin are the standard-of-care treatment for acute PVT in cirrhosis, although there is enthusiasm in a paradigm shift switching to DOACs for the treatment of acute PVT in cirrhosis, particularly since the release of DOAC antidotes. This article reviews the current Food and Drug Administration-approved DOACs, hepatic metabolism of DOACs, pharmacokinetics of DOACs in patients with cirrhosis, safety of DOACs (including bleeding, hepatotoxicity, and pregnancy), current treatment guidelines for PVT in cirrhosis, and studies evaluating the use of DOACs in cirrhosis and for the treatment of PVT in cirrhosis. The potential use of DOACs for PVT primary prophylaxis in at-risk patients with cirrhosis and the possible antifibrotic effects of DOACs are also discussed.

Sign in / Sign up

Export Citation Format

Share Document